Shares of vaccine maker Moderna fell Wednesday as Goldman Sachs lowered its rating after the biotech’s second cut to product ...

Moderna (MRNA) stock falls as Goldman Sachs downgrades the COVID-19 vaccine maker to Neutral from Buy, citing a lack of ...

In a report released today, Tyler Van Buren from TD Cowen maintained a Hold rating on Moderna (MRNA – Research Report), with a price target of ...

Shares of Moderna Inc. (NASDAQ: MRNA) are down 3.2% in premarket trading after a bear note from Goldman Sachs. The firm ...

Goldman Sachs downgraded Moderna (MRNA) to Neutral from Buy with a price target of $51, down from $99. The recent product revenue guidance ...

Goldman Sachs downgraded the vaccine maker to Neutral from Buy and slashed its stock-price target to $51 from $99 Wednesday.

Vaccine manufacturer Moderna has welcomed the Chancellor's announcements regarding major infrastructure schemes.

Moderna (NASDAQ: MRNA) shares fell over 3% ahead of Wednesday market open after Goldman Sachs cut its rating on the stock to Neutral from Buy. The downgrade follows a series of negative revisions to ...

More than 1,500 people who have sought support from the vaccine damage payment scheme after being injured or bereaved as a ...

Despite continued underperformance in 2024, the biotech sector enters 2025 with a brighter outlook driven by groundbreaking ...

Caroline Kennedy on Tuesday warned that her cousin Robert F. Kennedy Jr. is a “predator” ahead of his high-profile ...

We recently compiled a list of the Retirement Stock Portfolio: 10 Healthcare Stocks to Buy. In this article, we are going to ...